Ozempic shortages have European countries exploring bans on use of popular drug for weight loss
Belgium banned the use of Novo Nordisk’s diabetes drug Ozempic for weight loss this week, and Germany is considering a similar action amid shortages of the drug for diabetic patients.
Belgium announced the ban in the country’s Official Gazette on Tuesday as a royal decree, Reuters reported. Belgium first announced its plans to institute a ban on Ozempic for weight loss in October, with the country’s health minister saying that simply telling doctors not to prescribe it outside of its approved use hasn’t worked. The moves follow a similar one in the UK, where health authorities banned the use of Ozempic for weight loss in July. Wegovy, Novo’s product that uses the same active ingredient, launched for weight loss in the UK in September.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.